官方服务：
资源简介：
EGFR-TKI耐药相关研究的图片与表格
应用场景：
创建时间：
2022-08-09
相关数据集
Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
Targeted next-generation sequencing was performed in patients with IDH1 or IDH2 mutations. Here we describe 4 cases where mutant IDH isoform switching serves as a mechanism of acquired clinical resist
NIAID Data Ecosystem90
Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]
Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types
NIAID Data Ecosystem50
Summary of EGFR mutation status in cell samples of refractory cancer patientsa).
a)EGFR mutation status including wild-type (WT), E746-A750 del (del), L858R and T790M was determined by both IHC and RNA-LNA PCR clamp assays with 11 clinical samples of cancer patients refractory to
Figshare2015-12-02 更新20
Additional file 2 of Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Additional file 2: Table S2. Normalized read counts. CRISPR-Cas9 knockout screen-Normalized read counts (related to Figure 1).
NIAID Data Ecosystem50
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
NIAID Data Ecosystem30
